Onco Actu du 6 juillet 2017

	1. Biologie
Genomic analysis of key acute leukemia will likely yield new therapies [St. Jude Children's Hospital] Charting the genomic landscape of T-lineage acute lymphoblastic leukemia patients revealed insights that will guide research and help to lay the foundation for more targeted therapy.
Spreading cancer caught on film [BBC News] Scientists in Japan have developed a technique for finding cancerous cells throughout the body
	3.1.1 Tabac - e-cigs
Effectiveness of fire-safe cigarette laws still unclear [Reuters] The study found no evidence that so-called fire-safe cigarettes reduced the number of fires overall or fires started by cigarettes in the states where they were mandated, leaving the jury still out on whether these laws are a good way to protect people, the authors report in Injury Prevention.
	4. Dépistage, diagnostic et pronostic
Tumor Scanner Promises Fast 3D Imaging of Biopsies [NIH Director's Blog] The device works like a scanner for tissues, using a thin sheet of light to capture a series of thin cross sections within a tumor specimen without having to section it with a knife, as is done with conventional pathology.
	4.12 Biopsies liquides
Angle’s ovarian cancer test could beat current standard [PharmaTimes] The positive data from the ANG-001 and ANG-003 trials will enable Angle to move into the next phase of development of a commercial blood test addressing an estimated market size of £300 million per annum, the firm said.
	5. Traitements
Chemotherapy may spread cancer and trigger more aggressive tumours, warn scientists [The Telegraph] “In this study we only investigated chemotherapy-induced cancer cell dissemination in breast cancer. We are currently working on other types of cancer to see if similar effects are elicited.”
	5.12.1 Immunothérapies - partenariats
Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers [Celgene] BGB-A317 is an advanced clinical-stage investigational PD-1 inhibitor, which has been dosed in over 500 patients.
Celgene to buy BeiGene stake, to develop tumor cancer treatment [Reuters] BeiGene's advanced clinical-stage investigational tumor cancer treatment, BGB-A317, is a type of antibody that belongs to a class of immuno-oncology agents known as immune checkpoint inhibitors.
	5.12.3 Immunothérapies-combinaisons
Noxxon Pharma Announces First Patients Treated in Pase I/II Clinical Trial or Nox-A12 Combined with Keytruda in Metastatic and Colorectal Cancer [Noxxon] The open-label trial is designed to include 20 patients, 10 patients for each metastatic pancreas and colorectal cancer.
	5.12.4 Immunothérapies - Essais
Merck Provides Further Update on Three Multiple Myeloma Studies Evaluating KEYTRUDA® (pembrolizumab) in Combination with Pomalidomide or Lenalidomide [Merck] The FDA has determined that the data available at the present time indicate that the risks of KEYTRUDA plus pomalidomide or lenalidomide outweigh any potential benefit for patients with multiple myeloma.
FDA Halts Merck’s Multiple Myeloma Trials After Patient Deaths [Xconomy] Merck says the clinical holds in multiple myeloma do not affect the company’s other clinical trials testing the drug.
Troubled by deaths, FDA orders Merck to slam the brakes on three Keytruda studies [EndPoints] The latest news compounds a new headache for Merck just as it was putting some serious distance between itself and Bristol-Myers Squibb’s troubled rival PD-1 drug Opdivo.
FDA puts hold on Merck multiple myeloma trials after deaths [Reuters] The FDA said based on available data the risks of combining Keytruda with either of the Celgene medicines outweigh any potential benefit for patients with multiple myeloma.
	5.12.5 Immunothérapies - Pharma
Oxford BioMedica wins big contract for Novartis cell therapy [Reuters] The contract is for the supply of lentiviral vectors used to generate CTL019, a new kind of treatment for hard-to-treat leukemia that is expected to reach the market this year.
Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint [BMS] Opdivo (nivolumab) demonstrates superior recurrence-free survival versus Yervoy (ipilimumab) in Adjuvant Setting in CheckMate -238. These data will be submitted for presentation at an upcoming medical conference.
Bristol-Myers’ tarnished checkpoint star Opdivo beats out Yervoy in surprise PhIII [EndPoints] Seamus Fernandez notes that the results are likely to cannibalize Bristol’s Yervoy revenue, but will likely deliver a $1 billion boost to Opdivo as physicians steer away from the higher doses of highly toxic Yervoy.
	5.12.7 Immunothérapies - vaccins
Personalized cancer vaccines stake their claim to the next frontier in immuno-oncology [EndPoints] These first early forays in single arm studies involve technologies now in development at Neon Therapeutics and BioNTech, two biotechs on opposite sides of the Atlantic which share some common goals.
Personalized Cancer Vaccines Look Promising in Two New Studies [MIT Technology Review] Both Sahin and Wu say it took their research teams about three to four months to make each vaccine. They’ve gotten that process down to six weeks or less.
Personalized cancer vaccines vanquish melanoma in small but encouraging study [STAT] Researchers not involved in the study praised its results, but with caveats.
Personalized cancer vaccines show glimmers of success [Nature] Treatments tailored to a person's individual cancer mutations train immune system to attack tumours.
Personalized vaccines hold cancer at bay in two early trials [Reuters] The small Phase I trials now need to be followed by larger studies, but the impressive early results suggest the new shots work far better than first-generation cancer vaccines that typically targeted a single cancer characteristic.
	5.2 Pharma
Array BioPharma Submits New Drug Applications To FDA For Binimetinib And Encorafenib In Advanced Melanoma [Array] The submissions are supported by data from the pivotal Phase 3 COLUMBUS study, which showed that patients who received binimetinib and encorafenib had a significantly longer progression free survival (PFS) compared to patients receiving vemurafenib.
	5.3 Traitements - FDA, EMA, NICE...
Researchers Find Most Expert Speakers at FDA ODAC Meetings Receive Sizable Industry Payments [RAPS] Experts speaking on behalf of a pharmaceutical company at US Food and Drug Administration (FDA) Oncology Drug Advisory Committee (ODAC) meetings often receive hefty sums, raising questions about the relationships between the companies and the experts ahead of three ODAC meetings next week.
	5.5 ASCO
Making a Difference in Cancer Care With You [JCO] Over the past year as ASCO president, I have seen many challenges in many different arenas that prevent our curing every cancer. This experience leads me to admit I do not know when, but I do know how we will cure more, if not all, cancers, and how we will cure them faster by working together to overcome these challenges.
	6.13 Soins palliatifs
Health Affairs’ July Issue: Advanced Illness & End-Of-Life Care [Health Affairs] Often when needs are as much social and spiritual as they are medical, people are confronted with a fragmented, rescue-driven health care system that produces miraculous results but also disastrous failures.
	6.6 Publications
Variations in Databases Used to Assess Academic Output and Citation Impact [NEJM] The most accurate resource to calculate an academician’s bibliometric profile remains unclear. Meanwhile, to ensure proper credit for their contributions, we recommend that authors create and maintain a Google Scholar profile, merge cross-institutional Scopus profiles, and create an ORCID identifier to include in manuscript submissions whenever possible.
	6.8 Communication
A newspaper’s murky partnership with a regional oncology center: boosting revenue but misleading readers [HealthNewsReview] This arrangement is clearly serving the cancer clinic–which gets potential new patients, since all the links from this site go directly to the clinic’s website–and the newspaper, which gets money. But it’s not serving readers, because the medical information is not useful and instead may be harmful.
	6.9 Controverses
French scientist fined for failure to disclose industry ties [Nature] The case illustrates that researchers and physicians who are encouraged to work closely with industry need to understand what constitutes a conflict of interest, and to be aware of the need for transparency regarding outside links, says Hervé Chneiweiss, a neuroscientist who is chairman of the ethics committee of the French biomedical-research agency INSERM.